EN DE
Watch Hydreight Technologies Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Hydreight Technologies Inc (NURS) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Hydreight Technologies Inc stock C$0.59, price C$3.00, that is 80.5% below the price, quality 39 out of 100. Rating: strongly overvalued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CA · Based in US

HT Hydreight Technologies Inc logo Some data Nov 8, 2026

Hydreight Technologies Inc

NURS · V
Very expensive, weak quality

Our calculation puts a fair price 80% below what the stock costs today.

Low debt
Positive coverage
Profit last quarter +39% vs. a year ago.
Expensive Growth (revenue 5y +139.1 %/yr in CAD)
Thin margins · 8.6% net margin (TTM)
Mixed vs. peers (7/12)
Moderate moat 56/100 · thin data
Some data
Fair value C$0.5865 · Strongly overvalued
Quality 39/100
Negative free cash flow
⚠ Dilution
Watch Hydreight Technologies Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

C$5.36 C$0.2000 Fair Value C$0.5865 Dec 2022 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

47‑month range C$0.2000 – C$5.36 · fair‑value band C$0.4420 – C$0.7395 · the C$3.00 price screens above the C$0.5865 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.

Follow Hydreight Technologies in your weekly email

Every Wednesday you see whether Hydreight Technologies is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Hydreight Technologies Inc. operates in the digital health technology sector in the United States. The company develops a proprietary telemedicine service that allows users to book confidential health and wellness, and/or medical services through a mobile application.

Show moreShow less

It also provides consulting and advice in setting up health and wellness services, including assistance with finding experienced advisors in the areas of medical and privacy law, among others; medical liability insurance; pharmaceutical IV programs vetted by duly licensed pharmacists; procedural guides with respect to various services, such as a range of IV therapy treatments, GLP1, NAD, Botox, and fillers; and hiring, on-boarding, training, marketing, branding, payroll, and other accounting services.

In addition, the company offers an online pharmacy, which allows its network of medical practitioners to purchase pharmacy products from federally regulated pharmacies. Hydreight Technologies Inc. is headquartered in Las Vegas, Nevada.

Stock analysis

Hydreight Technologies Inc (NURS) currently trades at C$3.00, while our model-based Fair Value estimate is C$0.5865, 80% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of C$1.47 per share, and 0 of the 14 models we run sit above the C$3.00 price.

Bear case: the Asset-Based group reads lowest at C$0.1300, and 14 of the 14 models stay below the price. Data coverage for this calculation is medium.

Scenario range: C$0.4420 (bear) to C$0.7395 (bull), the price of C$3.00 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Hydreight Technologies Inc reported revenue of C$35.4M in FY2025 versus C$1.2M in FY2021, a compound +133.1%/yr. Reported net income was C$1.7M in FY2025.

Key figures

Market cap C$168M (≈ $119M) Micro · P/E ratio 23.1 · P/S ratio 2.14 · EPS (TTM) C$0.1300 · Net margin 8.6% · Return on equity 31.4% · Return on assets (EBIT) −42.1% (5-year average) · Operating margin 9.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 56 out of 100 (low confidence).

What moves the price

The share trades about 44% below its 52-week high and 26% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 3% fair-value upside, at −80%, NURS screens richer than that median.

Fair Value models

The price assumes far more growth than our models allow for, so the models scatter widely (C$0.1300 to C$1.50). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear C$0.4420 Fair Value C$0.5865 Bull C$0.7395
Price C$3.00 · Downside -80.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (C$0.1115 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income C$0.2900 C$0.3000 C$0.3400 74
EPV C$0.3900 C$0.4200 C$0.4500 71
ROIC Compounder C$0.4100 C$0.5000 C$0.5700 70
All 14 models by family
Earnings-Based
Graham-Dodd C$0.2100 C$1.50 C$2.10 61
Lynch FV C$0.7700 C$1.10 C$1.44 59
PEG = 1.0 C$0.7700 C$1.10 C$1.44 55
EPV C$0.3900 C$0.4200 C$0.4500 71
Multiples
P/E Multiple C$0.5200 C$0.6900 C$0.8700 63
P/S Multiple C$0.4000 C$0.5400 C$0.6700 58
P/B Multiple C$1.08 C$1.44 C$1.80 55
EV/EBIT C$0.5300 C$0.7000 C$0.8800 66
EV/EBITDA C$0.5200 C$0.7000 C$0.8700 67
EV/Revenue C$0.3800 C$0.5400 C$0.7000 53
Asset-Based
NCAV (Graham) C$0.0800 C$0.1300 C$0.1600 54
Economic Profit
Residual Income C$0.2900 C$0.3000 C$0.3400 74
ROIC Compounder C$0.4100 C$0.5000 C$0.5700 70
Growth Earnings
Growth-Adj P/E C$1.03 C$1.47 C$1.91 65

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 39/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 47
How much profit the company makes from its sales and capital
Quality Growth 60
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 78
Debt, balance sheet and risk of trouble
Investment 44
Does it invest with discipline instead of growing at any price?
Low Volatility 45
How calm the share price moves, does not count
Price momentum 10
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 10
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+120.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+102.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+139.1%
Start year 2020 (pandemic)
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−51.0% (2020) → 6.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed

NURS screens overvalued: fair value 80% below the price. Compare with Veeva Systems Inc →

Earlier news

News mood ⓘNews mood, the average tone of recent news (24 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive
Recent news coverage is more positive than average.

Compare Hydreight Technologies Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 117 stocks

Beats the industry median on 7/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 39 · Bottom 25%
Fair Value upside −80.5% · Bottom 25%
Profitability
Return on equity (12 months) 31.4% · Top 25%
Return on assets 5.0% · Above median
Net margin (12 months) 8.6% · Above median
Operating margin (12 months) 9.7% · Above median
Growth and dividend
Revenue growth (quarter YoY) 421.4% · Top 25%
Balance sheet
Debt / equity 0.42× · Highest 25%

Valuation Multiplesvs Health Information Services median · lower = cheaper

P/E (12 months) 23.1× · Cheaper than median
P/B 8.51× · Priciest 25%
P/S (12 months) 2.14× · Cheaper than median
EV/EBITDA 20.9× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 5
FUTURE (revenue growth)100 · sector 46
PAST (return on equity)100 · sector 10
HEALTH (low debt)79 · sector 98
DIVIDEND (yield)0 · sector 41

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Veeva Systems Inc VEEV $303.73 $334.10 +10% vs NURS
HealthEquity, Inc HQY $103.63 $113.99 +10% vs NURS
Doximity, Inc DOCS $32.51 $35.76 +10% vs NURS
Inventurus Knowledge Solutions Limited IKS ₹1,657 ₹1,823 +10% vs NURS
Waystar Holding WAY $28.35 $29.10 +3% vs NURS
Hinge Health, Inc HNGE $115.76 $51.25 −56% vs NURS
Pro Medicus Limited PME A$205.49 A$85.12 −59% vs NURS
BrightSpring Health Services, Inc BTSG $67.15 $25.72 −62% vs NURS
XtalPi Holdings 2228 HK$6.13 HK$1.53 −75% vs NURS
Privia Health Group PRVA $24.42 $5.52 −77% vs NURS

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Hydreight Technologies Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Hydreight Technologies Inc Fair Value". https://www.fairvalue-calculator.com/stock/NURS

Frequently asked questions

Is Hydreight Technologies Inc (NURS) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of C$0.5865 versus a price of C$3.00, about 80% lower (overvalued).
What is the fair value of NURS?
Our model-based fair value for Hydreight Technologies Inc is C$0.5865 (as of Nov 8, 2026), built from audited fundamentals. The current price: C$3.00.
What is the quality score of NURS?
Hydreight Technologies Inc has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hydreight Technologies Inc (NURS)?
Our model-based price target is the fair value of C$0.5865 (as of Nov 8, 2026) from 14 valuation models. Cautious scenario C$0.4420, optimistic scenario C$0.7395. It is a calculation from audited fundamentals, not an analyst target.
What is the Hydreight Technologies Inc stock forecast for 2026?
Our models put fair value at C$0.5865, about 80% lower versus a price of C$3.00 (overvalued). Cautious scenario C$0.4420, optimistic scenario C$0.7395. The calculation is refreshed regularly with new filings.
What is the revenue of Hydreight Technologies Inc (NURS)?
Hydreight Technologies Inc reported trailing-twelve-month revenue of about C$78.4M (latest available figure, as of Nov 8, 2026).
What is the intrinsic value of Hydreight Technologies Inc (NURS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hydreight Technologies Inc it is C$0.5865 per share (as of Nov 8, 2026), against a price of C$3.00. It is the blended result of 14 valuation models in 5 families (Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Hydreight Technologies Inc stock overvalued or undervalued in 2026?
As of Nov 8, 2026, NURS trades above its calculated fair value: price C$3.00, fair value C$0.5865, a gap of about −80% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NURS?
No. The price is what the market pays today (C$3.00); the fair value is what the company's own numbers justify (C$0.5865). For Hydreight Technologies Inc the two are C$2.41 per share apart. That gap is exactly why we show both numbers side by side.
How much is Hydreight Technologies Inc worth?
The market values Hydreight Technologies Inc at about C$168M (market capitalisation, as of Nov 8, 2026). Per share that is C$3.00; our models calculate a fair value of C$0.5865 per share.
What do the bullish and bearish scenarios say about NURS?
Our models span a range for Hydreight Technologies Inc: cautious scenario C$0.4420, base C$0.5865, optimistic C$0.7395 per share (as of Nov 8, 2026, price C$3.00). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of NURS?
Hydreight Technologies Inc trades at a price-to-earnings ratio of 23.1 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of C$0.5865 is built from several models across several years. Other multiples: P/B 8.5, P/S 2.1, EV/EBITDA 20.9.
How solid is the balance sheet of Hydreight Technologies Inc (NURS)?
Balance-sheet figures for Hydreight Technologies Inc (as of Nov 8, 2026): return on equity 31.4%, debt of 0.42 per unit of equity. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is NURS from its 52-week high?
Hydreight Technologies Inc trades at C$3.00, about 44% below its 52-week high of C$5.36 and 26% above the low of C$2.39 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of C$0.5865 is for.
Which stocks are comparable to Hydreight Technologies Inc?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hydreight Technologies Inc stock attractive at the current price?
The data as of Nov 8, 2026: price C$3.00, calculated fair value C$0.5865 (−80%), Quality Score 39/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NURS calculated?
We run Hydreight Technologies Inc through 14 models from 5 families: Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of C$0.5865 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Hydreight Technologies Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hydreight Technologies Inc (NURS)?
The closing price on Nov 6, 2026 was C$3.00. Our model-based fair value is C$0.5865, about 80% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hydreight Technologies Inc right now?
The price sits above even our optimistic bull case (C$0.7395). The favourable scenario is already priced in. Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts.

Key figures of Hydreight Technologies Inc

How large is the market capitalisation of Hydreight Technologies Inc (NURS)?
The market capitalisation of Hydreight Technologies Inc is C$168M (≈ $119M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Hydreight Technologies Inc (NURS)?
The price-to-sales ratio of Hydreight Technologies Inc is 2.14 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Hydreight Technologies Inc (NURS)?
Earnings per share at Hydreight Technologies Inc are C$0.1300 (price ÷ EPS = P/E 23.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Hydreight Technologies Inc (NURS)?
The net margin of Hydreight Technologies Inc is 8.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Hydreight Technologies Inc (NURS)?
The return on equity (ROE) of Hydreight Technologies Inc is 31.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hydreight Technologies Inc (NURS)?
On an EBIT basis the return on assets of Hydreight Technologies Inc is −42.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hydreight Technologies Inc (NURS)?
The operating margin of Hydreight Technologies Inc is 9.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Hydreight Technologies Inc (NURS)?
Revenue at Hydreight Technologies Inc is growing +421% versus a year earlier (3y avg +102%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Hydreight Technologies Inc (NURS)?
Earnings per share at Hydreight Technologies Inc are growing +38.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Hydreight Technologies Inc (NURS) generate?
The free cash flow of Hydreight Technologies Inc is −C$3.4M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Hydreight Technologies Inc (NURS) carry?
The net debt of Hydreight Technologies Inc is C$522 (fiscal year 2019). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Hydreight Technologies Inc in the live analysis

One click puts Hydreight Technologies Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.